Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA.

Pancreas. 2012 Jul;41(5):789-96. doi: 10.1097/MPA.0b013e31823b5f2e.

2.

A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA.

Clin Cancer Res. 2009 Oct 1;15(19):6137-47. doi: 10.1158/1078-0432.CCR-09-0696. Epub 2009 Sep 29.

3.

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE.

Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8.

4.

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA.

J Neurosurg. 2011 Jun;114(6):1662-71. doi: 10.3171/2010.11.JNS101214. Epub 2011 Feb 4.

PMID:
21294620
5.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA.

Br J Cancer. 2009 Oct 6;101(7):1114-23. doi: 10.1038/sj.bjc.6605297.

6.

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA.

Pancreas. 2010 Aug;39(6):913-22. doi: 10.1097/MPA.0b013e3181cbd908.

7.

Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.

Byeon HJ, Choi SH, Choi JS, Kim TH, Lee ES, Lee KC, Youn YS.

Biomed Pharmacother. 2014 Feb;68(1):65-9. doi: 10.1016/j.biopha.2013.10.010. Epub 2013 Nov 7.

PMID:
24268811
8.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.

Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA.

J Neurooncol. 2011 Jun;103(2):255-66. doi: 10.1007/s11060-010-0392-5. Epub 2010 Sep 10.

9.

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, Vickers SM.

Gut. 2008 May;57(5):634-41. doi: 10.1136/gut.2007.137802. Epub 2008 Jan 25.

10.
11.

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA.

Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23.

12.

Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.

Park B, Prasad S, Yadav V, Sung B, Aggarwal BB.

PLoS One. 2011;6(10):e26943. doi: 10.1371/journal.pone.0026943. Epub 2011 Oct 31. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/d4645c95-739f-4175-b753-b6fe0ba6063c.

13.

Biologic effect of neurogenesis in pancreatic cancer.

He D, Manzoni A, Florentin D, Fisher W, Ding Y, Lee M, Ayala G.

Hum Pathol. 2016 Jun;52:182-9. doi: 10.1016/j.humpath.2016.02.001. Epub 2016 Mar 2.

PMID:
26980040
14.

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V.

Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020. Epub 2015 Oct 24.

PMID:
26597578
15.

Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.

Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I.

Clin Cancer Res. 2006 Jul 1;12(13):4036-42.

16.

KAI1 inhibits lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo.

Liu X, Guo XZ, Li HY, Chen J, Ren LN, Wu CY.

Hepatobiliary Pancreat Dis Int. 2014 Feb;13(1):87-92.

PMID:
24463085
17.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

18.

Chemical generation of bispecific antibodies.

Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, Parish M, Murphy RE, Del Rosario J, Oates BD, Lai JY, Matin MJ, Ainekulu Z, Bhat A, Bradshaw CW, Woodnutt G, Lerner RA, Lappe RW.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13.

19.

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.

Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM.

MAbs. 2011 May-Jun;3(3):273-88. Epub 2011 May 1.

20.

Supplemental Content

Support Center